Active Stocks
Thu Apr 18 2024 10:35:17
  1. Tata Steel share price
  2. 161.85 1.12%
  1. Power Grid Corporation Of India share price
  2. 283.80 3.44%
  1. Wipro share price
  2. 449.40 0.18%
  1. Infosys share price
  2. 1,416.40 0.12%
  1. ITC share price
  2. 423.60 -0.55%
Business News/ Companies / Zydus Cadila recalls over 10,000 bottles of allergy drug in US
BackBack

Zydus Cadila recalls over 10,000 bottles of allergy drug in US

Zydus's drug recall is the seventh this year by an Indian company; the FDA classified the recall as Class II

The FDA classified the recall as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences. Photo: BloombergPremium
The FDA classified the recall as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences. Photo: Bloomberg

Mumbai: Indian drugmaker Zydus Cadila is recalling 10,200 bottles of an allergy-relief drug in the United States after another drug for high blood pressure was found in one of the bottles, the US Food and Drug Administration said on Friday.

The recall was voluntarily started by the company’s US unit, Zydus Pharmaceuticals USA Inc, on 8 May, due to the presence of the high blood pressure medicine atenolol in a bottle containing the allergy drug, promethazine hydrochloride.

Promethazine hydrochloride is commonly used to treat allergic disorders, nausea, vomiting, difficulty sleeping, as well as for pre-operative sedation.

The FDA classified the recall as Class II, which means use of or exposure to the recalled products may cause temporary or medically reversible adverse health consequences.

The bottles being recalled carry an expiry date of September 2015, according to the FDA post.

A Zydus spokesman did not immediately respond to a request for comment.

Recalls of drugs are not uncommon.

However, Zydus’s drug recall is the seventh this year by an Indian company, and follows those by other large drugmakers including Wockhardt Ltd, Ranbaxy Laboratories Ltd , Dr. Reddy’s Laboratories Ltd, Lupin Ltd, Sun Pharmaceutical Industries Ltd and Glenmark Pharmaceuticals Ltd.

The incidents come at a time when the FDA has increased its scrutiny of Indian drugmakers after the agency banned exports from manufacturing plants of some top drugmakers, including Ranbaxy and Wockhardt, upon finding quality control lapses. REUTERS

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 30 May 2014, 03:38 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App